{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:29:12Z","timestamp":1785554952733,"version":"3.56.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jneuroim.2020.577280","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T04:01:01Z","timestamp":1591329661000},"page":"577280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155"],"prefix":"10.1016","volume":"345","author":[{"given":"Li","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyun","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shougang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2020.577280_bb0005","doi-asserted-by":"crossref","first-page":"606","DOI":"10.5334\/tohm.451","article-title":"Tremor associated with chronic inflammatory demyelinating polyneuropathy and anti-neurofascin-155 Antibodies","volume":"8","author":"Bailly","year":"2018","journal-title":"Tremor. Other. Hyperkinet."},{"issue":"20","key":"10.1016\/j.jneuroim.2020.577280_bb0010","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV- negative patients: a report of 57 cases from the research on adverse drug events and reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.jneuroim.2020.577280_bb0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0960-9822(01)00680-7","article-title":"Neurofascin is a glial receptor for the paranodin\/ Caspr-contactin axonal complex at the axoglial junction","volume":"12","author":"Charles","year":"2002","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jneuroim.2020.577280_bb0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.jneuroim.2020.577280_bb0025","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2020.577280_bb0030","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/WNL.0000000000002418","article-title":"Neurofascin-155 IgG4 in chronic inflflammatory demyelinating polyneuropathy","volume":"86","author":"Devaux","year":"2016","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2020.577280_bb0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2020.577280_bb0040","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1093\/brain\/aww189","article-title":"Auto-antibodies to contactin associated protein 1 (Caspr) in two patients with painful inflflammatory neuropathy","volume":"139","author":"Doppler","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2020.577280_bb0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1085-9489.2005.0010206.x","article-title":"History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation","volume":"10","author":"Dyck","year":"2005","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jneuroim.2020.577280_bb0050","series-title":"Parkinson\u2019s Disease and Movement Disorders","first-page":"225","article-title":"Clinical rating scale for tremor","author":"Fahn","year":"1993"},{"key":"10.1016\/j.jneuroim.2020.577280_bb0055","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/eji.200737557","article-title":"Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with rituximab","volume":"38","author":"Ferraro","year":"2008","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.jneuroim.2020.577280_bb0060","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/mus.26010","article-title":"Pollard JD, Kiernan MC.Neurofascin-155 IGG4 neuropathy: pathophysiological insights, spectrum of clinical severity and response to treatment","volume":"57","author":"Garg","year":"2018","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.jneuroim.2020.577280_bb0065","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp.2005.081547","article-title":"A modified peripheral neuropathy scale: the overall neuropathy limitations scale","volume":"77","author":"Graham","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2020.577280_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1115","article-title":"Association of neurofascin IgG4 and atypical chronic inflammatory demyelinating polyneuropathy: a systematic review and meta analysis","volume":"8","author":"Hu","year":"2018","journal-title":"Brain. Behav."},{"issue":"8093","key":"10.1016\/j.jneuroim.2020.577280_bb0075","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","article-title":"Controlled trial prednisolone in acute polyneuropathy","volume":"2","author":"Hughes","year":"1978","journal-title":"Lancet."},{"key":"10.1016\/j.jneuroim.2020.577280_bb0080","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jneuroim.2019.05.004","article-title":"Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis","volume":"332","author":"Jing","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2020.577280_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1529-8027.2010.00245.x","volume":"15","author":"Joint Task Force of the eFNS and the PNS","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jneuroim.2020.577280_bb0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2016.10.013","article-title":"IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: clinical significance and diagnostic utility of a conventional assay","volume":"301","author":"Kadoya","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2020.577280_bb0095","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/0167-5699(94)90273-9","article-title":"Molecular mechanisms regulating CD19, CD20 and CD22 gene expression","volume":"15","author":"Kehrl","year":"1994","journal-title":"Immunol. Today"},{"key":"10.1016\/j.jneuroim.2020.577280_bb0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MD.0b013e3182431ef6","article-title":"Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients","volume":"91","author":"Khosroshahi","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.jneuroim.2020.577280_bb0105","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/jnnp-2016-314895","article-title":"Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with antineurofascin-155 and anticontactin-1 antibodies","volume":"23","author":"Koike","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2020.577280_bb0110","first-page":"241","article-title":"Immunological memory stabilizing autoreactivity","volume":"305","author":"Manz","year":"2006","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.jneuroim.2020.577280_bb0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jneuroim.2017.05.002","article-title":"Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies","volume":"309","author":"Mathey","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2020.577280_bb0120","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood.V99.6.2154","article-title":"The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression","volume":"99","author":"Medina","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.jneuroim.2020.577280_bb0125","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/jnnp.72.5.596","article-title":"Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies","volume":"72","author":"Merkies","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2020.577280_bb0130","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2004-08-2992","article-title":"Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells","volume":"105","author":"Muehlinghaus","year":"2005","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.jneuroim.2020.577280_bb0135","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/acn3.248","article-title":"Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy","volume":"2","author":"Ogata","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2020.577280_bb0140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/acn3.539","article-title":"Head and voice tremor improving with immunotherapy in an anti-NF155 positive CIDP patient","volume":"5","author":"Painous","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2020.577280_bb0145","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1212\/NXI.0000000000000149","article-title":"Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins","volume":"2","author":"Querol","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2020.577280_bb0150","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrneurol.2017.84","article-title":"Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications","volume":"13","author":"Querol","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2020.577280_bb0155","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Raschbuilt overall disability scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"van Nes","year":"2011","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.jneuroim.2020.577280_bb0160","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/acn3.645","article-title":"Regulatory B cells in myasthenia gravis are differentially affected by therapies","volume":"5","author":"Yilmaz","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572820301648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572820301648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:36:22Z","timestamp":1759048582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572820301648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":32,"alternative-id":["S0165572820301648"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577280","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577280"}}